{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:42:03Z","timestamp":1790534523434,"version":"4.1.0"},"reference-count":131,"publisher":"Hogrefe Publishing Group","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Zeitschrift f\u00fcr Kinder- und Jugendpsychiatrie und Psychotherapie"],"published-print":{"date-parts":[[2018,5,1]]},"abstract":"<jats:p> Abstract. Objective: Research has implicated glutamatergic projections between the various frontal subregions in the pathogenesis of compulsivity and impulsivity. Reducing striatal glutamate release, or antagonising the action of glutamate at its receptors, may therefore represent viable treatment strategies. Several glutamatergic agents with regulatory approval for other indications are available and may be of potential benefit in the treatment of compulsivity\/impulsivity in psychiatric disorders in paediatric patients. Method: This review was performed according to PRISMA guidelines and evaluates available scientific literature concerning the use of glutamatergic agents in these patients, in order to determine their reported effectiveness\/efficacy and tolerability\/safety. Results: Out of a total of 1,426 publications, 21 trials examining six glutamatergic substances in patients with obsessive-compulsive disorder, autism spectrum disorders, and attention deficit\/hyperactivity disorder were included. Conclusions: Trial designs as well as results were heterogeneous and thus comparability was limited. Available data support the hypothesis that glutamatergic agents are of potential value in the treatment of compulsivity\/impulsivity in children and adolescents. Based on the data reviewed, memantine and N-acetylcysteine suggest the best risk-benefit profile for future trials. Riluzole should primarily be further investigated in adults. Clinical research of this nature is a key element of the TACTICS Consortium project funded by the European Union (FP7). <\/jats:p>","DOI":"10.1024\/1422-4917\/a000546","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T16:04:26Z","timestamp":1505750666000},"page":"246-263","source":"Crossref","is-referenced-by-count":19,"title":["Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry: a Systematic Review of the Literature"],"prefix":"10.1024","volume":"46","author":[{"given":"Konstantin","family":"Mechler","sequence":"first","affiliation":[{"name":"Research Group of Paediatric                     Psychopharmacology, Department of Child and Adolescent Psychiatry and                     Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim,                     University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"H\u00e4ge","sequence":"additional","affiliation":[{"name":"Research Group of Paediatric                     Psychopharmacology, Department of Child and Adolescent Psychiatry and                     Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim,                     University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Schweinfurth","sequence":"additional","affiliation":[{"name":"Research Group of Paediatric                     Psychopharmacology, Department of Child and Adolescent Psychiatry and                     Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim,                     University of Heidelberg, Mannheim, Germany"},{"name":"Center for Diagnostics and Crisis                     Intervention, Department of Psychiatry and Psychotherapy, University Psychiatric                     Centers (UPK) Basel, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Glennon","sequence":"additional","affiliation":[{"name":"Department of Cognitive Neuroscience,                     Donders Institute for Brain, Cognition and Behavior, Radboud University, Radboud                     University Medical Centre and Karakter Child and Adolescent Psychiatry                     University Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick M.","family":"Dijkhuizen","sequence":"additional","affiliation":[{"name":"Biomedical MR Imaging and Spectroscopy                     Group, Center for Image Sciences, University Medical Center, Utrecht, The                     Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"Murphy","sequence":"additional","affiliation":[{"name":"Sackler Institute for Translational                     Neurodevelopment, Department of Forensic and Neurodevelopmental Sciences,                     Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College                     London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Durston","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brain Center                     Rudolf Magnus, University Medical Center Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Williams","sequence":"additional","affiliation":[{"name":"Centre for Neuroimaging Sciences,                     Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College                     London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"K. Buitelaar","sequence":"additional","affiliation":[{"name":"Department of Cognitive Neuroscience,                     Donders Institute for Brain, Cognition and Behavior, Radboud University, Radboud                     University Medical Centre and Karakter Child and Adolescent Psychiatry                     University Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Banaschewski","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent                     Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical                     Faculty Mannheim, University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf W.","family":"Dittmann","sequence":"additional","affiliation":[{"name":"Research Group of Paediatric                     Psychopharmacology, Department of Child and Adolescent Psychiatry and                     Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim,                     University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"the","family":"TACTICS Consortium","sequence":"additional","affiliation":[{"name":"Research Group of Paediatric                     Psychopharmacology, Department of Child and Adolescent Psychiatry and                     Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim,                     University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"101","reference":[{"key":"c1","author":"Abdel-Ahad P.","year":"2013","journal-title":"Non-Antidepressant Pharmacological Treatment of Obsessive Compulsive Disorder: A Comprehensive Review"},{"key":"c2","first-page":"283","author":"Aman M. G.","year":"1995","journal-title":"The Aberrant Behavior Checklist-Community: factor validity and effect of subject variables for adults in group homes"},{"key":"c3","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"c4","first-page":"167","author":"Berk M.","year":"2013","journal-title":"The promise of N-acetylcysteine in neuropsychiatry"},{"key":"c5","first-page":"525","author":"Berry-Kravis E.","year":"2006","journal-title":"Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial"},{"key":"c6","first-page":"237","author":"Biederman J.","year":"2005","journal-title":"Attention-deficit hyperactivity disorder"},{"key":"c7","first-page":"1102","author":"Billstedt E.","year":"2007","journal-title":"Autism in adults: symptom patterns and early childhood predictors. Use of the DISCO in a community sample followed from childhood"},{"key":"c8","first-page":"231","author":"Bloch M. H.","year":"2013","journal-title":"N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial"},{"key":"c9","first-page":"24","author":"Brennan B. P.","year":"2013","journal-title":"A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder"},{"key":"c10","first-page":"52","author":"Bristot Silvestrin R.","year":"2013","journal-title":"Animal model of autism induced by prenatal exposure to valproate: altered glutamate metabolism in the hippocampus"},{"key":"c11","first-page":"379","author":"Budimirovic D. B.","year":"2011","journal-title":"What Can We Learn about Autism from Studying Fragile X Syndrome?"},{"key":"c12","first-page":"525","author":"Carlsson M. L.","year":"1998","journal-title":"Hypothesis: is infantile autism a hypoglutamatergic disorder"},{"key":"c13","first-page":"401","author":"Carlsson M. L.","year":"2000","journal-title":"On the role of cortical glutamate inobsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions."},{"key":"c14","first-page":"5","author":"Carlsson M. L.","year":"2001","journal-title":"On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder."},{"key":"c15","first-page":"331","author":"Carrey N.","year":"2002","journal-title":"Glutamatergic changes with treatment in attention deficit hyperactivity disorder: a preliminary case series"},{"key":"c16","first-page":"1735","author":"Chakrabarty K.","year":"2005","journal-title":"Glutamatergic dysfunction in OCD."},{"key":"c17","first-page":"1282","author":"Chamberlain S. R.","year":"2006","journal-title":"Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania"},{"key":"c18","first-page":"574","author":"Chez M. G.","year":"2007","journal-title":"Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability."},{"key":"c19","first-page":"620","author":"Ciociola A. A.","year":"2014","journal-title":"How drugs are developed and approved by the FDA: current process and future directions"},{"key":"c20","author":"Cohen J.","year":"1988","journal-title":"Statistical Power Analysis for the Behavioral Sciences: Lawrence Erlbaum Associates"},{"key":"c21","first-page":"279","author":"Collier R.","year":"2009","journal-title":"Drug development cost estimates hard to swallow"},{"key":"c22","first-page":"257","author":"Conners C. K.","year":"1998","journal-title":"The revised Conners\u2019 Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity"},{"key":"c23","first-page":"427","author":"Constantino J. N.","year":"2003","journal-title":"Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised."},{"key":"c24","first-page":"219","author":"Coric V.","year":"2003","journal-title":"Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder"},{"key":"c25","first-page":"424","author":"Coric V.","year":"2005","journal-title":"Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial"},{"key":"c26","first-page":"2199","author":"Davis C.","year":"2007","journal-title":"Dopamine transporter gene (DAT1) associated with appetite suppression to methylphenidate in a case-control study of binge eating disorder"},{"key":"c27","first-page":"78","author":"Dean O.","year":"2011","journal-title":"N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action"},{"key":"c28","first-page":"391","author":"Dean O. M.","year":"2012","journal-title":"Minocycline: therapeutic potential in psychiatry"},{"key":"c29","first-page":"1424","author":"Douglass H. M.","year":"1995","journal-title":"Obsessive-compulsive disorder in a birth cohort of 18-year-olds: prevalence and predictors"},{"key":"c30","author":"DuPaul G. J.","year":"1998","journal-title":"ADHD rating scale-IV : checklists, norms, and clinical interpretation"},{"key":"c31","first-page":"1178","author":"Durston S.","year":"2011","journal-title":"Differentiating frontostriatal and fronto-cerebellar circuits in attention-deficit\/hyperactivity disorder"},{"key":"c32","first-page":"141","author":"Erickson C. A.","year":"2007","journal-title":"A retrospective study of memantine in children and adolescents with pervasive developmental disorders"},{"key":"c33","first-page":"264","author":"Erickson C. A.","year":"2011","journal-title":"Open-label riluzole in fragile X syndrome"},{"key":"c34","first-page":"75","author":"Erickson C. A.","year":"2013","journal-title":"Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome"},{"key":"c35","author":"European Medicines Agency.","year":"2014","journal-title":"Product Information: Axura 10 mg film-coated tablets"},{"key":"c36","author":"European Medicines Agency.","year":"2015","journal-title":"EPAR Product Information: RILUTEK 50 mg film-coated tablets"},{"key":"c37","author":"European Medicines Agency.","year":"2015","journal-title":"EPAR summary for the public: Memantine Merz (memantine hydrochloride)"},{"key":"c38","first-page":"723","author":"Farrell L. J.","year":"2013","journal-title":"Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy"},{"key":"c39","first-page":"19","author":"Findling R. L.","year":"2007","journal-title":"A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit\/hyperactivity disorder combined type"},{"key":"c40","first-page":"591","author":"Fineberg N. A.","year":"2010","journal-title":"Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review"},{"key":"c41","first-page":"764","author":"Flament M. F.","year":"1988","journal-title":"Obsessive Compulsive Disorder in Adolescence: An Epidemiological Study."},{"key":"c42","author":"Food and Drug Administration, U.","year":"2006","journal-title":"Package Insert: Acetadote\u00ae (acetylcysteine) Injection."},{"key":"c43","author":"Food and Drug Administration, U.","year":"2009","journal-title":"DESCRIPTION: RILUTEK"},{"key":"c44","author":"Food and Drug Administration, U.","year":"2010","journal-title":"Mecial Review NDA 22525, Namenda"},{"key":"c45","author":"Food and Drug Administration U.","year":"2015","journal-title":"PROVIGIL"},{"key":"c46","first-page":"72","author":"Gantois I.","year":"2013","journal-title":"Chronic administration"},{"key":"c47","first-page":"666","author":"Garber K. B.","year":"2008","journal-title":"Fragile X syndrome"},{"key":"c48","first-page":"349","author":"Gerrard P.","year":"2007","journal-title":"Mechanisms of modafinil: A review of current research"},{"key":"c49","first-page":"783","author":"Ghaleiha A.","year":"2013","journal-title":"Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial"},{"key":"c50","first-page":"505","author":"Ghaleiha A.","year":"2013","journal-title":"Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial"},{"key":"c51","first-page":"223","author":"Ghanizadeh A.","year":"2013","journal-title":"N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial"},{"key":"c52","author":"Ghanizadeh A.","year":"2013","journal-title":"A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders"},{"key":"c53","first-page":"308","author":"Goldfield G. S.","year":"2007","journal-title":"Methylphenidate reduces energy intake and dietary fat intake in adults: a mechanism of reduced reinforcing value of food?"},{"key":"c54","first-page":"189","author":"Grados M.","year":"2008","journal-title":"Do all obsessive-compulsive disorder subtypes respond to medication?"},{"key":"c55","first-page":"756","author":"Grant J. E.","year":"2009","journal-title":"N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study."},{"key":"c56","first-page":"761","author":"Grant P.","year":"2007","journal-title":"An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder"},{"key":"c57","first-page":"309","author":"Grant P.","year":"2010","journal-title":"Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder"},{"key":"c58","first-page":"1453","author":"Grant P. J.","year":"2014","journal-title":"12-Week, Placebo-Controlled Trial of Add-on Riluzole in the Treatment of Childhood-Onset Obsessive-Compulsive Disorder"},{"key":"c59","author":"Guy W.","year":"1976","journal-title":"US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs"},{"key":"c60","first-page":"297","author":"Hagerman R.","year":"2012","journal-title":"Fragile X syndrome and targeted treatment trials"},{"key":"c61","first-page":"44","author":"Hall S. S.","year":"2008","journal-title":"Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome"},{"key":"c62","author":"Hardan A.","year":"2014","journal-title":"Efficacy and Safety of Memantine in a Global, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study in Children With Autism Spectrum Disorder: Poster Session: The 167th annual meeting of the American Psychiatric Association"},{"key":"c63","author":"Hendren R.","year":"2014","journal-title":"Results From a Two-Part, Open-Label\/Double-Blind Randomized, Placebo-Controlled Trial and an Open-Label Extension"},{"key":"c64","first-page":"994","author":"Hersh J. H.","year":"2011","journal-title":"Health supervision for children with fragile X syndrome"},{"key":"c65","first-page":"324","author":"Heyman I.","year":"2001","journal-title":"Prevalence of obsessive-compulsive disorder in the British nationwide survey of child mental health"},{"key":"c66","first-page":"3","author":"Hollander E.","year":"1996","journal-title":"Obsessive-compulsive and spectrum disorders: overview and quality of life issues"},{"key":"c67","author":"Horder J.","year":"2013","journal-title":"Reduced subcortical glutamate\/glutamine in adults with autism spectrum disorders"},{"key":"c68","first-page":"166","author":"Hosenbocus S.","year":"2013","journal-title":"Memantine: a review of possible uses in child and adolescent psychiatry"},{"key":"c69","author":"Jacquemont S.","year":"2011","journal-title":"Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056"},{"key":"c70","first-page":"984","author":"Javitt D. C.","year":"2004","journal-title":"Glutamate as a therapeutic target in psychiatric disorders"},{"key":"c71","first-page":"1065","author":"Jensen P. S.","year":"1997","journal-title":"Comorbidity in ADHD: implications for research, practice, and DSM-V"},{"key":"c72","first-page":"61","author":"Johnson J. W.","year":"2006","journal-title":"Mechanism of action of memantine"},{"key":"c73","first-page":"1314","author":"Joshi G.","year":"2013","journal-title":"Psychiatric comorbidity and functioning in a clinically referred population of adults with autism spectrum disorders: a comparative study"},{"key":"c74","first-page":"1741","author":"Kamath P.","year":"2007","journal-title":"Suicidal behavior in obsessive-compulsive disorder"},{"key":"c75","first-page":"1442","author":"Kessler R. C.","year":"2005","journal-title":"Patterns and predictors of attention-deficit\/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication"},{"key":"c76","first-page":"541","author":"Klassen A. F.","year":"2004","journal-title":"Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit\/hyperactivity disorder"},{"key":"c77","first-page":"52","author":"Koob G. F.","year":"1997","journal-title":"Drug abuse: hedonic homeostatic dysregulation"},{"key":"c78","first-page":"1111","author":"Kotecha S. A.","year":"2002","journal-title":"A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission"},{"key":"c79","first-page":"181","author":"Kretschmer B. D.","year":"1998","journal-title":"Riluzole, a glutamate release inhibitor, and motor behavior"},{"key":"c80","first-page":"254","author":"Lafleur D. L.","year":"2006","journal-title":"N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder"},{"key":"c81","first-page":"978","author":"Lambert M. P.","year":"1972","journal-title":"Mechanism of D-cycloserine action"},{"key":"c82","first-page":"1728","author":"Laupacis A.","year":"1988","journal-title":"An assessment of clinically useful measures of the consequences of treatment"},{"key":"c83","first-page":"147","author":"Leigh M. J.","year":"2013","journal-title":"A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome"},{"key":"c84","first-page":"21","author":"Lewin A. B.","year":"2006","journal-title":"A neuropsychiatric review of pediatric obsessive-compulsive disorder: etiology and efficacious treatments"},{"key":"c85","first-page":"283","author":"Ludolph A. G.","year":"2010","journal-title":"Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations"},{"key":"c86","first-page":"24","author":"Mahgoub N.","year":"2011","journal-title":"The effect of riluzole augmentation in a patient with treatment-resistant obsessive-compulsive disorder, taking two other glutaminergic agents"},{"key":"c87","first-page":"299","author":"Mancuso E.","year":"2010","journal-title":"Treatment of pediatric obsessive-compulsive disorder: a review"},{"key":"c88","first-page":"231","author":"Martinez-Raga J.","year":"2013","journal-title":"Educational needs for an underdiagnosed condition"},{"key":"c89","first-page":"239","author":"Marzullo L.","year":"2005","journal-title":"An update of N-acetylcysteine treatment for acute acetaminophen toxicity in children"},{"key":"c90","first-page":"9","author":"McDougle C. J.","year":"2005","journal-title":"Neurochemistry in the pathophysiology of autism"},{"key":"c91","first-page":"216","author":"McLennan Y.","year":"2011","journal-title":"Fragile x syndrome"},{"key":"c92","first-page":"712","author":"McQuay H. J.","year":"1997","journal-title":"Using numerical results from systematic reviews in clinical practice"},{"key":"c93","author":"Melmed R.","year":"2014","journal-title":"Results From an Open-Label, International Trial"},{"key":"c94","first-page":"1006","author":"Moher D.","year":"2009","journal-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement"},{"key":"c95","author":"Moher D.","year":"2001","journal-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials"},{"key":"c96","first-page":"378","author":"Monaghan D. T.","year":"1985","journal-title":"an autoradiographic analysis"},{"key":"c97","author":"Naaijen J.","year":"2015","journal-title":"A review of magnetic resonance spectroscopy studies"},{"key":"c98","first-page":"1491","author":"Nestadt G.","year":"2009","journal-title":"Obsessive-compulsive disorder: subclassification based on co-morbidity"},{"key":"c99","author":"Owley T.","year":"2006","journal-title":"A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders"},{"key":"c100","first-page":"11","author":"Parellada M.","year":"2014","journal-title":"The neurobiology of autism spectrum disorders"},{"key":"c101","author":"Paribello C.","year":"2010","journal-title":"Open-label add-on treatment trial of minocycline in fragile X syndrome"},{"key":"c102","first-page":"699","author":"Parsons C. G.","year":"2007","journal-title":"Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system \u2013 too little activation is bad, too much is even worse"},{"key":"c103","first-page":"314","author":"Pittenger C.","year":"2011","journal-title":"Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment"},{"key":"c104","first-page":"363","author":"Pittenger C.","year":"2008","journal-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up"},{"key":"c105","first-page":"386","author":"Polanczyk G.","year":"2007","journal-title":"Epidemiology of attention-deficit\/hyperactivity disorder across the lifespan"},{"key":"c106","first-page":"434","author":"Polanczyk G. V.","year":"2014","journal-title":"ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis"},{"key":"c107","first-page":"1227","author":"Pop A. S.","year":"2014","journal-title":"Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056\/Mavoglurant"},{"key":"c108","first-page":"2115","author":"Posey D. J.","year":"2004","journal-title":"A pilot study of D-cycloserine in subjects with autistic disorder"},{"key":"c109","first-page":"1150","author":"Prosser G. A.","year":"2013","journal-title":"Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by the antibiotic D-cycloserine"},{"key":"c110","first-page":"253","author":"Ramachandran G.","year":"2015","journal-title":"Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications"},{"key":"c111","first-page":"1247","author":"Rodriguez C. I.","year":"2010","journal-title":"Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial"},{"key":"c112","first-page":"1210","author":"Rosenberg D. R.","year":"2000","journal-title":"Genetic and imaging strategies in obsessive-compulsive disorder: potential implications for treatment development"},{"key":"c113","first-page":"1096","author":"Rosenberg D. R.","year":"2000","journal-title":"Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine"},{"key":"c114","first-page":"287","author":"Rubia K.","year":"2010","journal-title":"Disorder-specific dysfunction in right inferior prefrontal cortex during two inhibition tasks in boys with attention-deficit hyperactivity disorder compared to boys with obsessive-compulsive disorder"},{"key":"c115","first-page":"601","author":"Rubia K.","year":"2011","journal-title":"Disorder-specific dysfunctions in patients with attention-deficit\/hyperactivity disorder compared to patients with obsessive-compulsive disorder during interference inhibition and attention allocation"},{"key":"c116","first-page":"844","author":"Scahill L.","year":"1997","journal-title":"Children\u2019s Yale-Brown Obsessive Compulsive Scale: reliability and validity"},{"key":"c117","first-page":"1228","author":"Shaffer D.","year":"1983","journal-title":"A childrens global assessment scale (cgas)."},{"key":"c118","first-page":"976","author":"Silverman J. L.","year":"2010","journal-title":"Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP"},{"key":"c119","first-page":"45","author":"Sourial M.","year":"2013","journal-title":"Progress toward therapeutic potential for AFQ056 in Fragile X syndrome"},{"key":"c120","first-page":"651","author":"Starcevic V.","year":"2008","journal-title":"Symptom subtypes of obsessive-compulsive disorder: are they relevant for treatment?"},{"key":"c121","first-page":"1073","author":"Storch E. A.","year":"2010","journal-title":"A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder"},{"key":"c122","author":"Thalheimer W.","year":"2002","journal-title":"How to calculate effect sizes from published research: A simplified methodology"},{"key":"c123","first-page":"62","author":"Ting J. T.","year":"2008","journal-title":"Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder"},{"key":"c124","first-page":"169","author":"Turic D.","year":"2004","journal-title":"Follow-up of genetic linkage findings on chromosome 16p13: evidence of association of N-methyl-D aspartate glutamate receptor 2A gene polymorphism with ADHD"},{"key":"c125","author":"U. S. National Library of Medicine.","year":"2014","journal-title":"HUMAN PRESCRIPTION DRUG LABEL: ACETYLCYSTEINE"},{"key":"c126","first-page":"433","author":"Utari A.","year":"2010","journal-title":"Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures"},{"key":"c127","first-page":"731","author":"Virring A.","year":"2017","journal-title":"Sleep Problems and Daily Functioning in Children With ADHD: An Investigation of the Role of Impairment, ADHD Presentations, and Psychiatric Comorbidity"},{"key":"c128","first-page":"127","author":"Vrij F. M. de","year":"2008","journal-title":"Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice"},{"key":"c129","first-page":"352","author":"Wigal S. B.","year":"2006","journal-title":"Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit\/hyperactivity disorder: pooled analysis of 3 randomized, double-blind, placebo-controlled studies"},{"key":"c130","author":"Wolff J. J.","year":"2013","journal-title":"Repetitive and self-injurious behaviors: associations with caudate volume in autism and fragile X syndrome"},{"key":"c131","first-page":"1941","author":"Zeeuw P. de","year":"2012","journal-title":"Decreased frontostriatal microstructural organization in attention deficit\/hyperactivity disorder"}],"container-title":["Zeitschrift f\u00fcr Kinder- und Jugendpsychiatrie und Psychotherapie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/1422-4917\/a000546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T03:37:18Z","timestamp":1615952238000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/1422-4917\/a000546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,1]]},"references-count":131,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5,1]]}},"alternative-id":["10.1024\/1422-4917\/a000546"],"URL":"https:\/\/doi.org\/10.1024\/1422-4917\/a000546","relation":{},"ISSN":["1422-4917","1664-2880"],"issn-type":[{"value":"1422-4917","type":"print"},{"value":"1664-2880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,1]]}}}